CAS · 763113-22-0
Product Overview
Olaparib is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | white powder |
|---|---|
| HPLC assay: | 98.0–102.0% |
| Identification: | IR/HPLC |
| Water: | 0.5% max |
| Residue on ignition: | 0.1% max |
| Ethanol: | 0.5% max |
| Dichloromethane: | 0.06% max |
| Any single impurity: | 0.1% max |
| Total impurity: | 0.5% max |
| Solubility: | Slightly soluble in tetrahydrofuran, sparingly soluble in N,N-Dimethylformamide, very slightly soluble in acetonitrile, and practically insoluble in water. |
| Microbial limit - TAMC: | 1000 cfu/g max |
| Microbial limit - TYMC: | 100 cfu/g max |
| E. coli: | Absent per g |
Applications
1. Targeted Cancer Therapy
Olaparib is a targeted anti-cancer drug used primarily in the treatment of cancers associated with BRCA1/2 gene mutations, including:
Ovarian cancer (especially relapsed or platinum-sensitive)
Breast cancer (HER2-negative, BRCA-mutated)
Prostate cancer (metastatic castration-resistant prostate cancer)
Pancreatic cancer (metastatic BRCA-mutated types)
It's typically used as:
Monotherapy in patients with BRCA mutations
Maintenance therapy following platinum-based chemotherapy
2. Combination Therapy
Olaparib is increasingly being studied and used in combination with other anti-cancer agents such as:
Bevacizumab
Abiraterone
Immune checkpoint inhibitors
These combinations aim to enhance efficacy by attacking cancer through multiple mechanisms.
3. Clinical Trials and Research
Used extensively in:
Clinical research to assess its effectiveness in other tumor types
Exploring its synergy with radiotherapy and DNA-damaging agents
Studying applications in non-BRCA and HRD-positive (homologous recombination deficient) tumors
Benefits
✅ Targeted Action
Specifically affects cancer cells with defective DNA repair while sparing healthy cells, reducing systemic toxicity.
✅ Prolongs Progression-Free Survival
Significantly improves progression-free survival (PFS) in patients with BRCA-mutant cancers compared to placebo or chemotherapy alone.
✅ Oral Administration
Available as convenient oral tablets, which improves patient compliance and quality of life.
✅ Non-Chemotherapy Option
Provides a non-cytotoxic alternative for long-term maintenance, often delaying the need for more aggressive therapies.
✅ Expanding Indications
Approved for multiple cancer types, and ongoing trials suggest potential broader applicability to other solid tumors.
Conclusion
Olaparib (CAS 763113-22-0) is a groundbreaking PARP inhibitor that plays a vital role in precision oncology. By exploiting weaknesses in DNA repair pathways of certain cancer cells, it offers effective, targeted treatment for patients with BRCA mutations or HRD-positive tumors. Its growing use in multiple cancer types, favorable administration route, and research potential make it a cornerstone in modern cancer therapeutics.
Previous
Next